4.8 Article

Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant

期刊

SCIENCE TRANSLATIONAL MEDICINE
卷 10, 期 460, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aap9489

关键词

-

资金

  1. Memorial Sloan Kettering Center for Microbes, Inflammation, and Cancer
  2. Leonard Tow Foundation
  3. National Institute of Allergy and Infectious Diseases of the NIH [U01 AI12427]
  4. Lymphoma Foundation
  5. Susan and Peter Solomon Divisional Genomics Program
  6. NIH [P30 CA008748]
  7. Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center

向作者/读者索取更多资源

Antibiotic treatment can deplete the commensal bacteria of a patient's gut microbiota and, paradoxically, increase their risk of subsequent infections. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), antibiotic administration is essential for optimal clinical outcomes but significantly disrupts intestinal microbiota diversity, leading to loss of many beneficial microbes. Although gut microbiota diversity loss during allo-HSCT is associated with increased mortality, approaches to reestablish depleted commensal bacteria have yet to be developed. We have initiated a randomized, controlled clinical trial of autologous fecal microbiota transplantation (auto-FMT) versus no intervention and have analyzed the intestinal microbiota profiles of 25 allo-HSCT patients (14 who received auto-FMT treatment and 11 control patients who did not). Changes in gut microbiota diversity and composition revealed that the auto-FMT intervention boosted microbial diversity and reestablished the intestinal microbiota composition that the patient had before antibiotic treatment and allo-HSCT. These results demonstrate the potential for fecal sample banking and posttreatment remediation of a patient's gut microbiota after microbiota-depleting antibiotic treatment during allo-HSCT.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据